Systematic methodological review of health state values in glaucoma cost-utility analyses.

IF 3.1 3区 医学 Q1 ECONOMICS
European Journal of Health Economics Pub Date : 2024-11-01 Epub Date: 2024-02-27 DOI:10.1007/s10198-023-01663-x
Kevin Kennedy, Gurkaran Sarohia, Dominik Podbielski, Simon Pickard, Jean-Eric Tarride, Feng Xie
{"title":"Systematic methodological review of health state values in glaucoma cost-utility analyses.","authors":"Kevin Kennedy, Gurkaran Sarohia, Dominik Podbielski, Simon Pickard, Jean-Eric Tarride, Feng Xie","doi":"10.1007/s10198-023-01663-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Describing the characteristics and sources of health state utility values and reporting practice in the literature of cost-utility analyses facilitates an understanding of the level of the transparency, validity, and generalizability of cost-utility analyses. Improving the quality of reporting will support investigators in describing the incremental value of emerging glaucoma interventions.</p><p><strong>Objective: </strong>To describe the state of practice among published glaucoma cost-utility analysis studies, focusing on valuation of health and the quality of reporting.</p><p><strong>Evidence review: </strong>We searched several databases including Medline, CINHAL, Embase, Web of Science, Scopus, Biosis previews, the Health Economic Evaluations Database, and the NHS Economic Evaluation Database (NHS EED). We included full-text, English, published cost-utility analyses of glaucoma interventions with quality-adjusted life years (QALYs) as the primary outcome measure to calculate incremental cost-utility ratios. Excluded studies were non-English language, reviews, editorials, protocols, or other types of economic studies (cost-benefit, cost-minimization, cost-effectiveness). Study characteristics, operational definitions of glaucoma health states and health state utilities were extracted. The original source of the health utility was reviewed to determine the scale of measurement and the source of preference weighting. Items from the Systematic Review of Utilities for Cost-Effectiveness (SpRUCE checklist) were used to assess the reporting and quality of health utilities in glaucoma CUA.</p><p><strong>Findings: </strong>43 CUAs were included, with 11 unique sources of health utilities. A wide range of health utilities for the same Hodapp-Parrish-Anderson glaucoma health states were reported; ocular hypertension (0.84-0.95), mild (0.68-0.94), moderate (0.57-0.92), advanced (0.58-0.88), severe/blind (0.46-0.76), and bilateral blindness (0.26-0.5). Most studies reported the basis for using health utilities (34, 79%) and any assumptions or adjustments applied to the health utilities (22, 51%). Few studies reported a framework for assessing the relevance of health utilities to a decision context (8, 19%). Even fewer (3, 7%) applied a systematic search strategy to identify health utilities and used a structured assessment of quality for inclusion. Overall, reporting has not improved over time.</p><p><strong>Conclusions and relevance: </strong>This review describes that few CUAs describe important rationale for using health state utility values. Including additional details on the search, appraisal, selection, and inclusion process of health utility values improves transparency, generalizability and supports the assessment of the validity of study conclusions. Future investigations should aim to use health utilities on the same scale of measurement across health states and consider the source and relevance to the decision context/purpose of conducting that cost-utility study.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Health Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10198-023-01663-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: Describing the characteristics and sources of health state utility values and reporting practice in the literature of cost-utility analyses facilitates an understanding of the level of the transparency, validity, and generalizability of cost-utility analyses. Improving the quality of reporting will support investigators in describing the incremental value of emerging glaucoma interventions.

Objective: To describe the state of practice among published glaucoma cost-utility analysis studies, focusing on valuation of health and the quality of reporting.

Evidence review: We searched several databases including Medline, CINHAL, Embase, Web of Science, Scopus, Biosis previews, the Health Economic Evaluations Database, and the NHS Economic Evaluation Database (NHS EED). We included full-text, English, published cost-utility analyses of glaucoma interventions with quality-adjusted life years (QALYs) as the primary outcome measure to calculate incremental cost-utility ratios. Excluded studies were non-English language, reviews, editorials, protocols, or other types of economic studies (cost-benefit, cost-minimization, cost-effectiveness). Study characteristics, operational definitions of glaucoma health states and health state utilities were extracted. The original source of the health utility was reviewed to determine the scale of measurement and the source of preference weighting. Items from the Systematic Review of Utilities for Cost-Effectiveness (SpRUCE checklist) were used to assess the reporting and quality of health utilities in glaucoma CUA.

Findings: 43 CUAs were included, with 11 unique sources of health utilities. A wide range of health utilities for the same Hodapp-Parrish-Anderson glaucoma health states were reported; ocular hypertension (0.84-0.95), mild (0.68-0.94), moderate (0.57-0.92), advanced (0.58-0.88), severe/blind (0.46-0.76), and bilateral blindness (0.26-0.5). Most studies reported the basis for using health utilities (34, 79%) and any assumptions or adjustments applied to the health utilities (22, 51%). Few studies reported a framework for assessing the relevance of health utilities to a decision context (8, 19%). Even fewer (3, 7%) applied a systematic search strategy to identify health utilities and used a structured assessment of quality for inclusion. Overall, reporting has not improved over time.

Conclusions and relevance: This review describes that few CUAs describe important rationale for using health state utility values. Including additional details on the search, appraisal, selection, and inclusion process of health utility values improves transparency, generalizability and supports the assessment of the validity of study conclusions. Future investigations should aim to use health utilities on the same scale of measurement across health states and consider the source and relevance to the decision context/purpose of conducting that cost-utility study.

Abstract Image

青光眼成本效用分析中健康状态值的系统方法学回顾。
重要性:描述健康状态效用值的特征和来源以及成本效用分析文献中的报告实践有助于了解成本效用分析的透明度、有效性和可推广性。提高报告质量将有助于研究人员描述新出现的青光眼干预措施的增量价值:目的:描述已发表的青光眼成本效益分析研究的实践状况,重点关注健康估值和报告质量:我们检索了多个数据库,包括 Medline、CINHAL、Embase、Web of Science、Scopus、Biosis previews、健康经济评估数据库和 NHS 经济评估数据库 (NHS EED)。我们纳入了以质量调整生命年(QALYs)为主要结果指标的青光眼干预措施的全文、英文、已发表的成本效用分析,以计算增量成本效用比。不包括非英语研究、综述、社论、协议或其他类型的经济研究(成本效益、成本最小化、成本效益)。提取了研究特征、青光眼健康状态的操作定义和健康状态效用。对健康效用的原始来源进行审查,以确定测量尺度和偏好加权的来源。使用 "成本效益效用系统回顾"(SpRUCE)清单中的项目来评估青光眼CUA中健康效用的报告和质量:共纳入了 43 项 CUA,其中有 11 个独特的健康效用来源。对于相同的 Hodapp-Parrish-Anderson 青光眼健康状态,报告的健康效用范围很广:眼压高(0.84-0.95)、轻度(0.68-0.94)、中度(0.57-0.92)、晚期(0.58-0.88)、重度/失明(0.46-0.76)和双侧失明(0.26-0.5)。大多数研究报告了使用健康效用的依据(34 项,占 79%),以及对健康效用所做的任何假设或调整(22 项,占 51%)。很少有研究报告了评估健康效用与决策环境相关性的框架(8 项,19%)。更少的研究(3 项,7%)采用了系统的搜索策略来识别健康效用,并使用了结构化的质量评估来纳入研究。总体而言,随着时间的推移,报告情况并未得到改善:本综述指出,很少有 CUAs 描述了使用健康状况效用值的重要依据。纳入有关健康效用值的搜索、评估、选择和纳入过程的更多细节可提高透明度和可推广性,并有助于评估研究结论的有效性。未来的调查应着眼于在不同健康状态下使用相同测量尺度的健康效用值,并考虑其来源以及与开展成本效用研究的决策背景/目的的相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
2.30%
发文量
131
期刊介绍: The European Journal of Health Economics is a journal of Health Economics and associated disciplines. The growing demand for health economics and the introduction of new guidelines in various European countries were the motivation to generate a highly scientific and at the same time practice oriented journal considering the requirements of various health care systems in Europe. The international scientific board of opinion leaders guarantees high-quality, peer-reviewed publications as well as articles for pragmatic approaches in the field of health economics. We intend to cover all aspects of health economics: • Basics of health economic approaches and methods • Pharmacoeconomics • Health Care Systems • Pricing and Reimbursement Systems • Quality-of-Life-Studies The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements. Officially cited as: Eur J Health Econ
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信